Form 4: NovoCure Director Timothy Scannell Receives Equity Grant

Director Timothy J. Scannell acquired 11,610 restricted stock units and 16,999 stock options as part of an annual equity grant.

Summary

• Director Timothy J. Scannell was granted 11,610 restricted stock units (RSUs) on June 3, 2026.
• The director also received 16,999 stock options with an exercise price of $16.15 per share.
• Both the RSUs and the stock options are scheduled to vest on the earlier of the first anniversary of the grant date or the day before the 2027 annual general meeting.
• Following these transactions, the director's direct beneficial ownership of ordinary shares increased to 25,898.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule ensures retention and long-term commitment from board leadership.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Market volatility affecting the value of the granted equity instruments.
• Potential for future share price fluctuations impacting the exercise value of the granted options.

Future Outlook

The equity grants are subject to standard vesting conditions tied to the 2027 annual general meeting or the first anniversary of the grant date.

Management Comments

• The filing does not contain narrative management commentary.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, which is standard practice for publicly traded biotechnology companies to align board incentives with corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard corporate governance practices in the life sciences sector.
• Vesting periods of one year are typical for annual director equity awards among mid-cap biotechnology firms.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity awards on or before the 2027 annual general meeting.

Key Dates

Keywords

NovoCure, NVCR, Director Compensation, Equity Grant, Insider Transaction, Form 4